Alvotech is a privately owned, fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high quality biosimilar products. We are specialists in biogeneric product creation, all along the value chain from cell line development to commercial manufacturing. Our common goal: to be a global leader in the biosimilar space and to deliver high quality cost competitive products to patients worldwide.
We come from all around the world, bringing literally thousands of years of combined knowledge and expertise to our mission.
Our biosimilar assets include several biosimilar monoclonal antibodies and fusion proteins that are developed in our research & development centers located across Europe and are manufactured in our state-of-the-art facility in Reykjavik, Iceland.
We develop, produce and release our biosimilars in-house with the latest available technology and to the highest quality standards for the supply of finished and ready to commercialize products to our partners worldwide.
Alvotech brings together a group of world-class pharmaceutical executives with broad backgrounds and extensive experience in the biopharmaceutical industry. The leadership team is led by Alvotech’s CEO Mark Levick and the company’s founder Robert Wessman...
Our vision is to set a new standard for the future of biopharmaceuticals by bringing high quality biosimilars to market for life-threatening diseases for patients around the world.
Our aspiration is to build a leading global biopharmaceutical company, while focusing on the development and commercialization of medicines for the treatment of severe chronic conditions, including autoimmune diseases, osteoporosis and ophthalmic diseases.
At Alvotech, we seek to make life-changing high-quality biological drugs highly accessible to improve the quality of life of patients around the globe.
We are ready and committed to drive change in our rapidly evolving industry and set a new standard for the quality and accessibility of biosimilars.
Alvotech believes in a future where people suffering from debilitating conditions can hope for an improved quality of life.